We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

New Cancer Blood Test May Eliminate Need for Tissue Biopsy Specimens

By LabMedica International staff writers
Posted on 08 Dec 2015
Print article
Image: The “NEO” diagnostic platform allows doctors to determine the optimal targeted therapy for their cancer patients (Photo courtesy of NEO New Oncology).
Image: The “NEO” diagnostic platform allows doctors to determine the optimal targeted therapy for their cancer patients (Photo courtesy of NEO New Oncology).
The release of a new noninvasive cancer diagnostics test presents the physician with a painless and low-risk alternative to a tissue biopsy.

NEO New Oncology AG (Cologne, Germany) has announced the commercial launch of its “NEOliquid” assay. Requiring only a single blood sample, NEOliquid identifies clinically relevant, cancer-specific point mutations, insertions, deletions, and gene fusions in circulating cell-free DNA down to an allele frequency of 0.1%. In addition, NEOliquid is able to detect copy number alterations in minute amounts of circulating tumor DNA.

The "NEO" diagnostic platform enables physicians to select the optimal targeted therapy for their patients, including participation in suitable clinical trials. The cancer diagnostic test NEOliquid, which is available through certified pathologists, is an efficient, time-saving diagnostic assay that enables parallel analysis of all therapy-relevant genomic alterations in a blood sample. Within 10–15 working days NEOliquid detects mutations, amplifications, deletions, and translocations in over 39 genes relevant for the treatment of solid tumors.

The physician receives a detailed medical report within 10–15 working days after receipt of the patient’s sample. The medical report suggests suitable targeted therapies and an individualized recommendation for treatment if actionable genetic alterations are identified. In addition to treatment options, the report also provides information on relevant clinical trials.

Results of a study describing the clinical efficacy of NEOliquid conducted by investigators at Kantonsspital Luzern (Switzerland) and NEO New Oncology AG were published in the December 2015 online edition of the Journal of Thoracic Oncology.

“Blood-based genomic diagnostics has the potential to revolutionize cancer care,” said Dr. Lukas C. Heukamp, chief medical officer of NEO New Oncology AG. “We are very excited that with NEOliquid we are able to offer the clinician a tool to understand the patient’s cancer as a whole. NEOliquid facilitates detection of all therapeutically relevant genomic alterations without the need for a painful and often risky re-biopsy, while also being a powerful tool to display genomic differences between primary tumors and corresponding metastases, thereby capturing the entire heterogeneity of the disease.”

Related Links:

NEO New Oncology AG 
Kantonsspital Luzern


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.